Insight Molecular Diagnostics (IMDX) Receivables - Net (2020 - 2026)

Insight Molecular Diagnostics (IMDX) has 7 years of Receivables - Net data on file, last reported at $157000.0 in Q1 2026.

• Quarterly Receivables - Net fell 95.56% year-over-year to $157000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $157000.0 (down 95.56% YoY) and the FY2025 annual result came in at $1.1 million, down 29.5% from the prior year.
• Receivables - Net eased to $157000.0 in Q1 2026 per IMDX's latest filing, from $1.1 million in the prior quarter.
• The five-year high for Receivables - Net was $3.5 million in Q1 2025, with the low at $85000.0 in Q2 2024.
• Average Receivables - Net over 5 years is $1.1 million, with a median of $593000.0 recorded in 2023.
• Year-over-year, Receivables - Net jumped 2098.76% in 2025 and plunged 95.56% in 2026.
• Insight Molecular Diagnostics' Receivables - Net stood at $1.4 million in 2022, then slumped by 65.07% to $489000.0 in 2023, then surged by 227.2% to $1.6 million in 2024, then retreated by 29.5% to $1.1 million in 2025, then slumped by 86.08% to $157000.0 in 2026.
• Business Quant data shows IMDX's Receivables - Net at $157000.0 in Q1 2026, $1.1 million in Q4 2025, and $258000.0 in Q3 2025.